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Background: A shifted balance between T helper 1 (Th1)-type and Th2-type cytokines has been
hypothesised in cervical dysplasia
Aims: To evaluate possible deregulation of the cytokine network by estimating the expression of peripheral
cytokines in different stages of cervical disease and in relation to the presence or absence of high risk
human papillomavirus (HR-HPV).
Methods: Twenty one HR-HPV positive women with high grade cervical intraepithelial neoplasia (CIN II–III)
and 12 patients with invasive cervical carcinoma formed the study groups. Two control groups consisted of
10 HR-HPV positive and 11 HR-HPV negative women without CIN. Differences in leucocyte subgroups
were evaluated by a differential leucocyte count. Plasma concentrations of tumour necrosis factor a
(TNFa), TNFa receptors TNFRI and TNFRII, interferon c (IFNc), interleukin 2 (IL-2), IL-12, IL-4, and IL-10
were determined by enzyme linked immunosorbent assays.
Results: Leucocyte counts in patients with CIN III and carcinoma were significantly higher than in controls.
Plasma IFNc concentrations were significantly lower in patients with CIN III and carcinoma than in women
with CIN II or controls. Plasma concentrations of IL-12, IL-2, IL-4, and TNFa did not differ significantly
between groups, but significantly lower plasma concentrations of TNFRII were found in CIN III and
carcinoma compared with CIN II. IL-10 was detected with increased frequency in the plasma of patients
with CIN III and carcinoma.
Conclusions: These results indicate that a shift to a Th2-type cytokine pattern during the carcinogenesis of
cervical cancer occurs in women with CIN III lesions.
I
t is well established that high risk (HR) human papillo-
mavirus (HPV) types can cause the development of cervical
cancer.1–3 Most HPV infections are cleared without further
consequences for the host, but a certain proportion of
untreated infections with HR-HPV types may give rise to
high grade cervical intraepithelial neoplasia (CIN II–III) and
cervical cancer.4–6 There is evidence that cell mediated
immune responses of the host, both systemic and local, are
important determinants of the course of infection.7
‘‘The immune response is mediated through the release of
different cytokines, which can influence the synthesis and
actions of one another in the setting of an immunoregulat-
ing cytokine network’’
Cell mediated immune responses are regulated by T cells (T
helper (Th) cells and cytotoxic lymphocytes) in cooperation
with antigen presenting cells. The immune response is
mediated through the release of different cytokines, which
can influence the synthesis and actions of one another in the
setting of an immunoregulating cytokine network. Cytokines
in immune responses to infection are often classified as
immunostimulating (tumour suppressing) Th1-type cyto-
kines such as interferon c (IFNc), tumour necrosis factor a
(TNFa), interleukin 2 (IL-2), and IL-12, which mainly induce
cell mediated immunity, and Th2-type cytokines (IL-4, IL-5,
IL-6, IL-8, and IL-10), which are immunoinhibitory for cell
mediated responses and predominantly induce humoral
immunity.8 9 Qualitative and quantitative analyses of Th1-
type and Th2-type cytokine profiles have been used to
determine the immune response in several human diseases,
including HPV associated CIN.10 11 Studies describing circu-
lating cytokines in the plasma of patients with cervical
dysplasia or cancer are either scarce, deal with one or only a
few cytokines, or are contradictory and only incidentally
related to HR-HPV.12–20 In our present study, we analysed
changes in the peripheral cytokine pattern in HR-HPV
positive women with different stages of CIN compared with
HR-HPV positive and negative controls.
MATERIALS AND METHODS
Patients and controls
Women with abnormal cervical cytology referred to the
outpatient clinic of the gynaecology department of the
Erasmus University Medical Centre Rotterdam, the
Netherlands between July 2000 and August 2002 were
selected as the study group. HPV sampling and a cervical
biopsy were obtained from all participating women. Histology
results were defined as mild dysplasia (CIN I), moderate
dysplasia (CIN II), severe dysplasia (CIN III), or (micro)-
invasive cancer. An experienced pathologist revised all
histological samples. Our selection of study patients was
based on the presence of HR-HPV and the severity of CIN.
Women with CIN I lesions (mild dysplasia) were excluded
because more than 50% of our patients with CIN I were HR-
HPV negative. Healthy women who entered the outpatient
clinic for a regular sterilisation procedure were recruited as
Abbreviations: CIN, cervical intraepithelial neoplasia; CV, coefficient
of variation; HPV, human papillomavirus; HR, high risk; IFNc, interferon
c; IL, interleukin; MDC, minimal detectable concentration; PCR,
polymerase chain reaction; s, soluble; Th, T helper; TNFa, tumour
necrosis factor a; TNFR, tumour necrosis factor a receptor
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controls. Cervical cytology, histology, and HPV sampling were
obtained. Exclusion criteria for all participants were: post-
menopausal state, pregnancy at time of sampling, chronic
diseases (diabetes, allergy, or autoimmune disease), signs of
acute infection at the time of sampling, and an immuno-
compromised state. Two women with allergy, one woman
with an autoimmune disease, and one woman with an acute
infection at the time of sampling were excluded. With the
exception of oral contraceptives, patients did not use
medication on a regular base. Pain medication (non-steroidal
anti-inflammatory drugs) was omitted for at least two weeks
before sampling.
Our study protocol was approved by the hospital and
university ethics committee and all women voluntarily gave
signed informed consent.
HPV sampling and determination
Cervical scrapes for HPV detection and typing were taken by a
cervical biosampler (Accellon CombiH; Medscand Medical,
Malmo, Sweden). HPV testing was performed with the
consensus GP5+/GP6+ polymerase chain reaction (PCR)
enzyme immunoassay for 37 (sub)types, as described
previously.21 This test is clinically validated.22 We used
b globin PCR to identify sampling errors and to monitor for
PCR inhibitors. In addition, reverse line blot analysis was
performed on PCR enzyme immunoassay positive cases to
identify individual HPV types.
Blood sampling and processing
Peripheral venous blood samples were collected between 8.00
and 12.00 a.m. in sterile endotoxin free vacutainers (Becton
Dickinson, Meylan, France) with ethylenediaminetetraacetic
acid (EDTA) as anticoagulant and immediately centrifuged at
15006g for 10 minutes at 4 C˚. Plasma samples were stored at
280 C˚ until assayed.
A differential leucocyte count was performed in all blood
samples with a Sysmex XE-2100.
Cytokine determinations
All plasma samples were analysed by commercially available
enzyme linked immunoassays (Biosource Europe, Nivelle,
Belgium) for the cytokines TNFa, soluble TNFa receptors
(sTNFRI and sTNFRII), IFNc, IL-2, IL-4, IL-10, and IL-12.23
The detecting antibody in the immunoassay for IL-12
recognised the bioactive heterodimeric (p40 + p35) cytokine,
in addition to the p40 subunit homodimer. According to the
manufacturer, the minimal detectable concentrations
(MDCs) and intra-assay and interassay coefficients of
variation (CVs) were as follows: TNFa: MDC, 3 pg/ml; CVs,
, 6% and , 10%; sTNFRI: MDC, 50 pg/ml; CVs, , 7% and
, 10%; sTNFRII: MDC, 100 pg/ml; CVs, , 7% and , 10%;
IFNc: MDC, 2 pg/ml; CVs, , 5% and , 10%; IL-2: MDC,
7 pg/ml; CVs, , 6% and , 10%; IL-4: MDC, 2 pg/ml; CVs,
, 5% and , 7%; IL-10: MDC, 1 pg/ml; CVs, , 5% and
, 10%; IL-12 + p40: MDC, 1.5 pg/ml; CVs, , 10% and
, 10%.
Table 1 HPV typing in patients with cervical dysplasia
(CIN II, CIN III, and carcinoma) and in HR-HPV positive
controls
Controls n = 10 CIN II n = 10 CIN III n = 11 Carcinoma n=12
HR-HPV type HR-HPV type HR-HPV type HR-HPV type
31 31 31, 56 16
31 31 31, 18 16
31 16 16 16
31, 51, 56 16 16 16
56 16 16 18
59, 58, 56 16 16 18
59 16, 45, 56 16 18
35, 56 18, 39 16 18
52 39 16 18
16 52 16 (70) 33
33 (70)
82
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR,
high risk.
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Figure 1 Differential white blood cell counts in patients with high risk
human papillomavirus infection and cervical dysplasia and in high risk
HPV negative and high risk HPV positive controls. Data are shown as
mean¡SEM. *p ( 0.05 when compared with CIN II; **p , 0.01 when
compared with CIN II. ¤¤p , 0.01 when compared with CIN III. CIN,
cervical intraepithelial neoplasia; HPV, human papillomavirus.
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Figure 2 Plasma concentrations of IFN-c in high risk HPV positive
patients with cervical dysplasia and in high risk HPV negative and high
risk HPV positive controls. Median values are indicated by a horizontal
line. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus;
IFNc, interferon c.
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To calculate cytokine ratios, values below the detection
limit were assigned concentrations equal to one half of the
lower detection limit of each assay.
Statistical analysis
Cytokine data are presented as medians with ranges unless
stated otherwise. The non-parametric Kruskal-Wallis test and
Mann-Whitney U test were used as appropriate to assess
differences in cytokine values between groups, and
Spearman’s rank test was used to investigate correlations
between cytokine variables. A two tailed p value of 0.05 was
chosen to represent significance. Differences in leucocytes
and leucocyte subpopulations were evaluated by unpaired
two tailed t tests.
RESULTS
The study groups
Our study group comprised 33 women: 10 women with
moderate dysplasia (CIN II), 11 women with severe dysplasia
(CIN III), and 12 women with cervical carcinoma (10
squamous cell carcinomas, two adenocarcinomas). The
control groups consisted of 11 women without cervical
dysplasia without HR-HPV and 10 women without cervical
dysplasia but with a positive HR-HPV test. The mean (SD)
age was 32.4 (6.2) years for the HR-HPV negative controls,
27.9 (7.4) years for the HR-HPV positive controls, 33.4 (5.7)
years for patients with CIN II, 32.3 (5.5) years for those with
CIN III, and 35.6 (7.2) years for women with invasive
carcinoma.
Results of HPV determinations
HPV types 16, 18, and 31 were the most frequently detected
HR-HPV types (n = 18, n = 7, and n = 8, respectively).
Other HR types were less common: HPV-33, n = 2; HPV-35,
n = 1; HPV-39, n = 2; HPV-45, n = 1; HPV-51, n = 1;
HPV-52, n = 2; HPV-56, n = 6; HPV-58, n = 1; HPV-59,
n = 2; and HPV-82, n = 1. HPV-70 (low risk type) was
detected together with HPV-16 in one woman with CIN III
and as the single infecting agent in one of 12 patients with
carcinoma. There were 34 single and eight multiple HPV
infections. Table 1 summarises the HPV types within the
study groups.
The differential white blood cell count
The total leucocyte count was higher in patients with CIN III
and carcinoma than in CIN II and the control groups; the
difference between CIN II and CIN III was significant. The
neutrophil count showed a similar course, with a significant
increase from CIN II to carcinoma. Absolute monocyte and
lymphocyte counts varied significantly between groups, being
highest in women with CIN III. Figure 1 shows the results of
the differential white blood cell counts.
The cytokine profile
The results of cytokine assays were calculated for each 106
leucocytes, to stratify for possible different numbers of
cytokine producing leucocytes between study subjects.
Analysis of the peripheral cytokine profile in our study
groups revealed different courses for each of the eight
investigated cytokines. Differences between groups were
seen for IFNc concentrations, with a significant decrease
from CIN II to CIN III and carcinoma (p ( 0.01), as
summarised in fig 2.
There were no significant differences in plasma concentra-
tions of TNFa between the control and study groups. Both
TNF receptors were significantly correlated in all groups
(r = 0.973, p = 0.000 for HR-HPV negative controls;
r = 0.855, p = 0.002 for HR-HPV positive controls;
r = 0.979, p = 0.001 for patients with CIN II; r = 0.791,
p = 0.004 for patients with CIN III; and r = 0.748,
p = 0.005 for patients with invasive carcinoma). TNFRII
values were highest in HR-HPV positive controls. A sig-
nificant decrease was seen in patients with cervical carci-
noma compared with patients with CIN II. A similar pattern
was seen for TNFRI but the differences did not reach
significance. Figure 3 shows the median plasma concentra-
tions of TNFa and its two soluble receptors sTNFRI and
sTNFRII in all study groups.
There was a significant increase (p = 0.037) in plasma
concentrations of IL-2 between HR-HPV negative and HR-
HPV positive controls, but no other significant changes in IL-
2 values. IL-12 showed no significant differences between
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Figure 3 Plasma concentrations of TNFa and its soluble receptors
sTNFRI and sTNFRII in high risk HPV positive patients with cervical
dysplasia and in HPV negative and HPV positive controls. Median
concentrations were: TNFa, 106 pg/ml; sTNFRI, 106 ng/ml; and
sTNFRII, 106 ng/ml. CIN, cervical intraepithelial neoplasia; HPV, human
papillomavirus; TNFa, tumour necrosis factor a.
Table 2 Plasma concentrations of IL-4 and IL-10 in HR-HPV positive patients with cervical
dysplasia and in HR-HPV negative and positive controls
Group N
IL-4 . detection limit* in
x/N plasmas
IL-10 . detection limit* in
x/N plasmas
HR-HPV2 controls 11 2/11 2/11
HR-HPV+ controls 10 1/10 0/10
HR-HPV+ CIN II 10 2/10 0/10
HR-HPV+ CIN III 11 1/11 4/11
HR-HPV+ carcinoma 12 3/12 7/12
*Detection limit for IL-4, 2 pg/ml; detection limit for IL-10, 1 pg/ml.
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high risk; IL, interleukin.
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groups. IL-4 concentrations were below the detection limit in
most of the investigated plasma samples. IL-10 values were
below the detection limit in most control women and women
with moderate dysplasia, but were detectable in four of 11
patients with CIN III and seven of 12 invasive carcinomas.
Table 2 shows the data for IL-4 and IL-10.
A possible shift to increased expression of Th2-type
cytokines in patients with carcinoma was evaluated by
calculating the ratio of Th1-type cytokines IL-12, IFNc,
TNFa, and IL-2 to the Th2-type cytokine IL-10 for all study
groups. These ratios decreased significantly (p , 0.01 for
IFNc : IL-10, p = 0.02 and p , 0.01 for TNFa : IL-10,
p = 0.03 and p = 0.06 for IL-2 : IL-10) when patients with
carcinoma were compared with HR-HPV positive controls or
patients with CIN II. Figure 4 shows as an example the ratio
of IL-12 : IL-10.
DISCUSSION
Our data for the differential white blood cell counts in our
patients are in agreement with the results of Onsrud et al,
who reported increased leucocyte and neutrophil counts in
cervical carcinoma, probably induced by inflammation and
necrosis, and a decrease in absolute lymphocyte numbers in
comparison with healthy controls.24 Studies by Gemignani et
al and Balaram et al confirm these results.25 26 Stratification of
cytokine data for each 106 leucocytes seems justified.
Our study showed a significant decrease in circulating
IFNc concentrations in women with severe dysplasia and
invasive carcinoma. IFNc, secreted by Th1 cells, cytotoxic T
cells, and stimulated natural killer cells, is a major
contributor to an effective Th1-type cellular immune
response against HPV infections.7 Defective IFNc production
may be associated with persistent HPV infection and the
development of HPV related neoplasia.27 Our data for
circulating IFNc agree with these reports.
TNFa has been shown to act synergistically with IFNc on
cervical cancer cells by inducing apoptosis or necrosis.28 The
biological effects of TNFa are mediated by its two receptors
TNFRI and TNFRII. Both receptors are present on many cell
types and tissues; TNFRI is strongly expressed on cells that
are sensitive to the cytotoxic actions of TNFa, whereas
TNFRII is strongly expressed on stimulated T and B cells.29
Several agents including TNFa itself downregulate cell
surface expression of both receptors by proteolytic cleavage
of the extracellular domains that are shed as soluble
proteins—sTNFRI and sTNFRII—into the circulation.
Measurement of both soluble receptors, especially of
sTNFRII, is often used to assess Th1-type activity in cell
mediated immune responses.29–31 Our study showed no
significant differences in TNFa values between study groups.
However, there was a decrease in both soluble receptor
concentrations in the plasma of patients with carcinoma,
which reached significance for sTNFRII. This result reflects a
decrease in circulating TNFa and is in accordance with a
disturbed Th1-type immune response after progression to
CIN III and invasive carcinoma.
There were no significant differences in peripheral con-
centrations of the Th1-type cytokine IL-2 between our study
groups, except a slight increase (p = 0.037) between HR-
HPV negative and HR-HPV positive controls, which could
indicate an inflammatory response to the viral infection.
‘‘Interleukin 10 concentrations increased significantly with
the severity of dysplasia’’
A possible shift to Th2-type cytokines in the course of
development of cervical neoplasia may be reflected by
increased plasma concentrations of Th2-type cytokines IL-4
and IL-10. However, we found no significant differences in
IL-4 concentrations between our study groups. IL-10 con-
centrations increased significantly with the severity of
dysplasia. IL-10 is a potent immunosuppressive cytokine,
which inhibits T cell activation and Th1 cell differentiation.
This shift to Th2-type activity was characterised by Jacobs et
al as a significant decrease in the IL-12 : IL-10 ratio in
patients with high grade squamous intraepithelial lesions.20
IL-12, a key cytokine in the induction of cell mediated
immunity, promotes T cell differentiation into IFNc produ-
cing Th1 cells and induces IFNc production in NK cells. The
significant decrease in IL-12, IFNc, TNFa, and IL-2 relative to
IL-10 in patients with CIN III and carcinoma, as seen in our
study, supports and extends the finding of Jacobs et al of a
disturbed cellular immune response in the development of
severe cervical dysplasia and cervical carcinoma. The presence
of diseases that could influence circulating cytokine concen-
trations was excluded in all participants, so that presumably
these results are the consequence of HPV infection.
The changes that we found within the peripheral cytokine
network in cervical dysplasia and invasive cancer were not
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Figure 4 IL-12 : IL-10 ratio in plasma of high risk HPV positive patients
with cervical dysplasia and in high risk HPV negative and high risk HPV
positive controls. CIN, cervical intraepithelial neoplasia; HPV, human
papillomavirus; IL, interleukin.
Take home messages
N We found significant decreases in circulating interferon
c and tumour necrosis factor a receptor II and an
increase in interleukin 10 concentrations through the
different stages of dysplasia to invasive carcinoma
N These results indicate a shift towards a T helper 2-type
(Th2) cytokine pattern during the carcinogenesis of
cervical cancer in women with cervical intraepithelial
neoplasia (CIN) III lesions
N Vaccinations aimed at converting the Th2 response into
a Th1 response might be useful in the treatment of
patients with CIN II and II
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always in agreement with published data for individual
cytokines.12–20 In a study by Niwa et al,12 IFNc concentrations
in plasma from patients with cervical cancer and controls
were similar, whereas in a study by Lebrecht et al,13 IFNc
concentrations were below the detection limit in all groups.
Our results for plasma concentrations of TNFRI were in
accordance with the results of Sheu et al,17 who found
significantly lower serum concentrations of sTNFRI in
patients with cervical cancer when compared with women
with a benign disease, uterine myoma. However, they differ
from the results of Malejczyk et al,18 in whose study patients
with HPV-16 associated CIN I/II and CIN III lesions and with
HPV-16/18 associated squamous cervical cancer were com-
pared with healthy controls. There were no significant
differences in receptor values between women with CIN
lesions and controls, but both receptor concentrations
increased significantly in patients with cervical cancer.
Important factors that contribute to differences in results
compared with earlier studies include selection criteria for
controls and patients. In our study, we selected patients and
controls according to their state of infection with HR-HPV.
The single presence of low risk HPV type 70 in one woman
with cervical carcinoma could be explained by HR-HPV DNA
integrated via the L1 region in the cellular genome, which can
be missed by the GP5+/6+ PCR. With the exception of the
studies of Jacobs et al and Malejczyk et al, none of the above
mentioned studies investigated the presence of HPV.18 20
Moreover, stratification for leucocyte numbers might also
explain these discrepancies. Immunocompetent leucocytes
are the main producers of circulating cytokines. In contrast to
all other studies, we calculated our results according to the
leucocyte count and not for each millilitre of plasma. Finally,
analytical methods for the measurement of cytokines may
differ. Some studies used plasma, others serum, a choice that
influences the quantitative outcome (unpublished results,
2005). All studies used enzyme linked immunoassays, which
were produced by different manufacturers. This implies the
use of different antibody systems for cytokine binding and
quantification with different sensitivities.
Our results indicate a change to a Th2 cytokine pattern
already manifest in women with CIN III lesions. This
provides the theoretical base of the clinical policy to treat
all women with CIN III lesions. Furthermore, it might
indicate that, in patients with cervical cancer, vaccinations
should be directed towards conversion of the Th2 response
into a Th1 response, and that they may also be useful in
women with CIN II lesions.
In conclusion, our study showed characteristic changes
within the peripheral cytokine network during the course of
HR-HPV infection through different stages of dysplasia to
invasive carcinoma: a significant decrease in circulating IFNc
and sTNFRII and an increase in IL-10 concentrations. This
indicates a shift towards a Th2-type immune response in the
development of cervical cancer. The changes in cell mediated
immunity become manifest in patients with CIN III, which is
in line with the clinical observation that most CIN III lesions
do not regress spontaneously, and may ultimately progress
into invasive carcinoma if not properly treated.32
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